PAD Profile : Tamsulosin and dutasteride hydrochloride - Benign prostatic hyperplasia

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Tamsulosin and dutasteride hydrochloride - Benign prostatic hyperplasia

PAD Profile : Tamsulosin and dutasteride hydrochloride - Benign prostatic hyperplasia

Keywords :

BPH, LUTS, urinary retention

Brand Names Include :

Combodart

Traffic Light Status

Status 1 of 1.

Status :

Non Formulary

Formulations :

Not Specified

Trust Alignment :

Primary Care

ASPH

RSCH

SASH

SABP

Links :

BNF NICE SPC

NFD1

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type

Document

Review Date

Policy Statement

Combodart (tamsulosin and dutasteride) for LUTS in Men Policy Statement - PCN 295-2017 - Dec-17

01 June 2025

Committee Recommendations

Date

Committee Name

Narrative

03 June 2020

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

18 December 2017

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN does not recommend the use of the combination product Combidart® (dutasteride & tamsulosin) as a treatment option for lower urinary tract symptoms in men and has assigned a BLACK traffic light status to this treatment Patients whose treatment was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders

07.04.01. Drugs for urinary retention